Search 33,000+ CME courses
Back

StatPearls, LLC

  • COVID-19
  • Drugs, Investigational

Bamlanivimab

Bamlanivimab is an investigational drug developed for COVID-19 pneumonia. It is in the class of neutralizing monoclonal antibodies. This activity illustrates the indications, action, and contraindications for bamlanivimab as a novel agent in the treatment and post-exposure prophylaxis of COVID-19. It will highlight the mechanism of action, adverse events, monitoring, and relevant interactions pertinent to the healthcare team in managing patients with COVID-19, especially in an ambulatory setting.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 1 creditAMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 creditPharmacyUp to 1 credit

MOC types

ABS — Accredited CMEUp to 1 pointABPATH — Lifelong LearningUp to 1 pointABTS — Accredited CMEUp to 1 pointABIM — Medical KnowledgeUp to 1 pointABS — Self-AssessmentUp to 1 pointABP — Lifelong Learning and Self-AssessmentUp to 1 pointABTS — Self-AssessmentUp to 1 point

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Pricing

Fee varies

This provider typically $49–98

See fees on statpearls.com

Listed by the provider

  • Article / monograph / reference
  • Credit · Up to 1 credit
  • MOC · Up to 1 point
  • Fee varies · this provider typically $49–98
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 1, 2029 3 years left

More in Infectious Disease

See all

Courses from other providers in this specialty

More from StatPearls, LLC

See all

This provider’s courses closest to this one